US Supreme Court allows Maine PBM rules

12 June 2006

The US Supreme Court has, for the moment, refused to review an Appeal Court ruling into the constitutionality of a law from the US state of Maine that requires pharmacy benefit managers to disclose the discounts that they negotiate with drug companies. The decision, whilst disappointing to the Pharmaceutical Care Management Association, was described by the trade association as "an expected procedural move."

The PCMA believes that the law, passed in 2003, violates trade secrecy protections and is unconstitutional. The trade body also said that the Supreme Court could review the issues pertinent to the case within the next year, because of a similar law suit that is presently before the US District Court in Washington DC.

Among the provisions the PCMA is opposing, the Maine law requires PBMs to disclose the level of discounts that they receive from pharmaceutical firms to their clients, including members of the National Community Pharmacists Association, who welcome the Supreme Court's decision. Any discounts must also be passed on to pharmacies.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight